INOVIO has entered into multiple license and collaboration agreements with GeneOne Life Science, Inc. In September 2014, INOVIO and GeneOne announced a collaboration in which the companies will co-develop INOVIO’s DNA vaccine for Ebola through a Phase 1 clinical trial. In April 2015, the collaborators received an award from DARPA to further advance the Ebola project. The previous collaboration agreement with GeneOne for the Ebola vaccine was incorporated into this consortium funded by DARPA. In May 2015, a Phase 1 study of the DNA vaccine part of the project was initiated. Enrollment of this study has been completed.
In May 2015, we announced that we will advance a DNA vaccine for MERS into a Phase 1 clinical trial in healthy volunteers in a collaboration with GeneOne. Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1. In January 2016, the collaborators announced the initiation of recruitment for the Phase 1 study in partnership with the Walter Reed Army Institute of Research (WRAIR) in Maryland, where the trial was conducted. INOVIO announced results from the trial in June 2018.
In January 2016, INOVIO and GeneOne expanded the collaboration agreement to test and advance our DNA vaccine for preventing and treating Zika virus. INOVIO has an equity interest in GeneOne.